Acticor Biotech SA (7V7.SG)
| Previous close | 3.8200 |
| Open | 3.7600 |
| Bid | 3.8000 x N/A |
| Ask | 3.9400 x N/A |
| Day's range | 3.7600 - 3.8200 |
| 52-week range | 2.6800 - 5.7200 |
| Volume | |
| Avg. volume | 4 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
ACTICOR BIOTECH: Presentation of the Main Results of the Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024
PARIS, May 15, 2024--Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, including stroke, announces the presentation, on Wednesday, May 15, 2024 during the opening session of the 10th European Stroke Organisation Conference (ESOC), of the phase 2/3 study results, ACTISAVE, in the treatment of acute ischemic stroke.
- Business Wire
ACTICOR BIOTECH: Postponement of the Publication of Annual Results and Universal Registration Document 2023
PARIS, April 30, 2024--Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announces the postponement of the publication of its annual results and universal registration document including its 2023 annual financial report, originally scheduled for April 30, 2024.
- Business Wire
ACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment
PARIS, April 25, 2024--Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical-stage biotechnology company focused on the development of glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today announced the first results of its ACTISAVE phase 2/3 study in the treatment of acute ischemic stroke.
